Track Penumbra, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Penumbra, Inc. PEN · Stock Open Penumbra, Inc. in new tab

320.91 USD
P/E
80.79
EPS
3.97
P/B
7.98
ROE
10.67
Beta
0.69
Target Price
362.54 USD
Penumbra, Inc. logo

Penumbra, Inc.

🧾 Earnings Recap – Q3 2025

Penumbra reported strong third-quarter results for 2025, achieving $354.7 million in revenue driven by robust growth across its U.S. thrombectomy and embolization franchises, highlighting its competitive positioning and successful product innovation.

  • Total revenue increased by 17.8% year-over-year, with U.S. revenue growing 21.5% to $275 million.
  • The VTE franchise achieved remarkable 34% year-over-year growth, affirming its market leadership.
  • Gross margin expanded to 67.8%, with operating income at $48.8 million (13.8% of revenue), and future margins are projected to exceed 70%.
  • FDA clearance for breakthrough products Lightning Bolt 16 and Lightning Flash 3.0 enhances Penumbra's advanced CAVT device portfolio.
  • The integration of a dedicated embolization sales team has resulted in a 21.2% sequential revenue increase in this segment.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 24, 2027
P/E80.79
EPS3.97
Book Value40.18
Price to Book7.98
Debt/Equity13.22
% Insiders2.949%
Growth
Revenue Growth0.16%
Earnings Growth-0.09%
Estimates
Forward P/E52.02
Forward EPS6.17
Target Mean Price362.54

DCF valuation

Model fair value for Penumbra, Inc. (PEN)
Result
Sign in to run the valuation for PEN.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
13 analysts · consensus Hold · mean target 362.54 USD (low 320.00, high 374.00) · as of 12 Nov 2026
Low 320.00
Mean 362.54
High 374.00
Price 320.91
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Penumbra, Inc. Logo Penumbra, Inc. Analysis (PEN)

United States Health Care Official Website Stock

Is Penumbra, Inc. a good investment? Penumbra, Inc. (PEN) is currently trading at 320.91 USD. Market analysts have a consensus price target of 362.54 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 80.79. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: Penumbra, Inc. is expected to release its next earnings report on Feb. 24, 2027. The market consensus estimate for Forward EPS is 6.17.

Investor FAQ

Does Penumbra, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Penumbra, Inc.?

Penumbra, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Feb. 24, 2027. The company currently has a trailing EPS of 3.97.

Company Profile

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.

Exchange Ticker
NYQ (United States) PEN
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Nov. 16, 2014 1:10
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion